TregSpine

TregSpine appears to refer to an investigational **autologous regulatory T-cell therapy** program in amyotrophic lateral sclerosis rather than a well-established approved drug product. Based on the limited identifiable context, it is associated with ex vivo expansion and reinfusion of a patient's own regulatory T lymphocytes, sometimes studied together with low-dose interleukin-2 to enhance Treg survival and immunoregulatory activity. The intended therapeutic rationale is immune modulation in neuroinflammatory neurodegenerative disease, particularly ALS, but the exact product definition, manufacturing attributes, naming conventions, and mechanistic specifications for \"TregSpine\" are not sufficiently established in the available evidence to support a high-confidence detailed annotation.